Soligenix announced that it has received notice of intent to grant additional patents based on its patent application titled “Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines” in the United Kingdom and South Africa, with other international jurisdictions pending. The company has previously announced multiple issued patents within the same patent family in the United States. The allowed claims are directed to unique, proprietary compositions and methods related to combinations of glycoprotein antigens with nanoemulsion adjuvants comprising sucrose fatty acid esters prior to lyophilization. The described vaccine platform has previously been successfully applied to mono-, bi- and tri-valent candidates for Zaire ebolavirus, Sudan ebolavirus and Marburg marburgvirus, including monovalent vaccines SuVax (targeting Sudan ebolavirus) and MarVax (targeting Marburg marburgvirus).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX:
- Biotech Alert: Searches spiking for these stocks today
- Soligenix prices $4.75M public offering at 40c per share
- Soligenix: FDA grants orphan drug designation for active ingredient in MarVax
- Soligenix confirms FDA orphan designation for active ingredient in SuVax
- Soligenix prophylaxis against Sudan Ebola Virus gets FDA orphan designation